key: cord-0016271-cypicqkw authors: Chandan, Joht Singh; Chandan, Jaidev Kaur title: Considering gender-based violence in vaccine prioritisation strategies date: 2021-03-24 journal: Lancet DOI: 10.1016/s0140-6736(21)00532-8 sha: 9189aa762c545a563ff4b459f29e6483c4a219b9 doc_id: 16271 cord_uid: cypicqkw nan During the pandemic, there has been a surge of GBV, with expected long-term related excess morbidity and mortality. 2 Many countries have yet to implement adequate policies to counter or address this increase. In countries where such measures do exist, such as the UK, these often involve relaxing movement restrictions for those either at risk of or facing GBV. Although we welcome these measures, paradoxically, these strategies are coupled with unconsidered clinical risks for this cohort. The freedom to travel on public transport and to not be confined by household isolation might directly increase exposure to COVID-19 and subsequent transmission risks. Furthermore, exposure to GBV is disproportionately present in those from lower socioeconomic groups, and the effects of toxic stress carry an increased burden of cardiometabolic disease, both of which are risk factors for COVID-19 clinical severity. 3, 4 Despite these transmission and clinical risk factors, there is no mention of expediting vaccines for those experiencing GBV. 5 In light of this clinical safeguarding paradox affecting this vulnerable group, we strongly urge international policy makers to reconsider their vaccine prioritisation strategies. We declare no competing interests. COVID-19 vaccines and women's security Improving global surveillance of gender-based violence Risk of cardiometabolic disease and all-cause mortality in female survivors of domestic abuse Factors associated with COVID-19-related death using OpenSAFELY Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination For more on global policy measures for COVID-19 that factor in gender see https:// data.undp.org/gendertracker/ For UK guidance see